Transaction DateRecipientSharesTypePriceValue
23rd February 2021Stephen J Tulipano5,000Exercise of derivative$4.48$22,400.00
23rd February 2021Stephen J Tulipano5,000Open or private sale$58.60$292,991.50
22nd February 2021Stephen J Tulipano25,000Exercise of derivative$4.48$112,000.00
22nd February 2021Stephen J Tulipano102Open or private sale$60.00$6,120.00
22nd February 2021Stephen J Tulipano15,202Open or private sale$58.67$891,942.39
22nd February 2021Stephen J Tulipano9,696Open or private sale$59.29$574,841.90
19th February 2021Arthur Tzianabos10,000Open or private sale$60.67$606,652.00
19th February 2021Arthur Tzianabos10,000Exercise of derivative$2.19$21,900.00
8th February 2021Investments, Lp Rtw3,650,722Conversion of derivative$0.00
4th February 2021Investments, Lp Rtw625,000Open or private purchase$16.00$10,000,000.00
Stoke Therapeutics
Stoke Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Ticker: STOK
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1623526
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags